Skip to main content
. 2014 Aug 20;136(35):12283–12295. doi: 10.1021/ja504063c

Figure 5.

Figure 5

Characterization of Ac36AzGlcNAc. (A) NIH3T3 cells were treated with 200 μM Ac36AzGlcNAc or Ac4GlcNAz for the indicated times, followed by CuAAC and analysis by in-gel fluorescence scanning. (B) NIH3T3 cells were treated with 200 μM Ac36AzGlcNAc or Ac4GlcNAz for 16 h, at which time media was exchanged for fresh media containing 200 μM Ac4GlcNAc. Cells were harvested after the indicated lengths of time, subjected to CuAAC, and analyzed by in-gel fluorescence scanning. (C) HeLa cells were treated with 200 μM Ac36AzGlcNAc or Ac4GlcNAz for 5 h, at which time media was exchanged for fresh media containing 200 μM Ac4GlcNAc and 10 μM of the OGA inhibitor Thiamet-G or DMSO. Cells were harvested at the times indicated and subjected to CuAAC before being analyzed by in-gel fluorescence scanning.

HHS Vulnerability Disclosure